The Trump administration’s rescheduling order moved FDA-approved marijuana drug products and certain state-regulated medical marijuana products from Schedule I to Schedule III. But for Americans who grow their own at home, the most basic question, did anything actually change for me?, depends entirely on which cannabis attorney you ask. We asked four. They disagree. On… Keep Reading
President Trump signed an executive order on April 18 directing the FDA to fast-track review of psychedelic therapies and committing $50 million to ibogaine research. The psychedelics community is cautiously optimistic, and watching closely. President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate research into psychedelic therapies and allocating $50… Keep Reading
